Jason Broderick
Advertisement
Articles by Jason Broderick
Advertisement
Latest Updated Articles
Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term AnalysesPublished: February 18th 2022 | Updated:
Atezolizumab Fails to Improve DFS in RCC Following ResectionPublished: September 10th 2022 | Updated:
P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple MyelomaPublished: February 14th 2025 | Updated:
PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPCPublished: June 6th 2022 | Updated:
TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder CancerPublished: June 8th 2021 | Updated:
Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial CarcinomaPublished: October 22nd 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5